An Overview and Interpretation of Important Clinical Studies
on Non-small Cell Lung Cancer in 2021.
10.3779/j.issn.1009-3419.2022.101.19
- Author:
Bin GAN
1
;
Siyang LIU
1
;
Yilong WU
1
Author Information
1. Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
- Publication Type:Review
- Keywords:
Adjuvant therapy;
Immunotherapy;
Lung neoplasms;
Personalized medicine;
Targeted therapy
- MeSH:
Carcinoma, Non-Small-Cell Lung/surgery*;
Combined Modality Therapy;
Humans;
Immunotherapy;
Lung Neoplasms/surgery*;
Quality of Life
- From:
Chinese Journal of Lung Cancer
2022;25(5):295-302
- CountryChina
- Language:Chinese
-
Abstract:
Though the coronavirus disease is still raging in 2021, clinical research on non-small cell lung cancer (NSCLC) did not stop. However, benefiting from advances in lung cancer treatment modality, NSCLC patients have experienced significant improvements in overall survival and quality of life. Currently, research advances on targeted therapy and immunotherapy have together transformed the status of postoperative adjuvant therapy and established a new standard treatment modality for resectable NSCLC. There are equally important research advances in locally advanced and advanced NSCLC, including new treatment modalities, new therapeutic agents, etc., all of which bringing more options for clinical treatment. These therapies will bring changes to NSCLC and will gradually lead to the chronicity of lung cancer in the foreseeable future. Therefore, this paper reviews important studies that will change clinical practice in NSCLC treatment and noteworthy research advances in 2021.
.
